Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 1/2004

01-07-2004

Two Entities of Precursor T-Cell Lymphoblastic Leukemia/Lymphoma Based on Radiologic and Immunophenotypic Findings

Authors: Yasushi Onishi, Yoshihiro Matsuno, Ukihide Tateishi, Akiko Miyagi Maeshima, Masahiko Kusumoto, Takashi Terauchi, Shigeru Kusumoto, Naohiro Sekiguchi, Kazuki Tanimoto, Takashi Watanabe, Yukio Kobayashi, Kensei Tobinai

Published in: International Journal of Hematology | Issue 1/2004

Login to get access
Metadata
Title
Two Entities of Precursor T-Cell Lymphoblastic Leukemia/Lymphoma Based on Radiologic and Immunophenotypic Findings
Authors
Yasushi Onishi
Yoshihiro Matsuno
Ukihide Tateishi
Akiko Miyagi Maeshima
Masahiko Kusumoto
Takashi Terauchi
Shigeru Kusumoto
Naohiro Sekiguchi
Kazuki Tanimoto
Takashi Watanabe
Yukio Kobayashi
Kensei Tobinai
Publication date
01-07-2004
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2004
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1532/IJH97.04061

Other articles of this Issue 1/2004

International Journal of Hematology 1/2004 Go to the issue

Case Report

t(11;18)-Bearing Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Responding to Cladribine

OriginalPaper

Existence of Leukemic Clones Resistant to Both Imatinib Mesylate and Rituximab before Drug Therapies in a Patient with Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Case Report

Sustained Cytogenetic Remission Induced by Imatinib Mesylate in a Chronic Myeloid Leukemia Patient Who Had a Relapse into Lymphoid Crisis after Allogeneic Hematopoietic Stem Cell Transplantation

Case Report

Exaggerated Cutaneous Response to Mosquito Bites in a Patient with Chronic Lymphocytic Leukemia

OriginalPaper

Treatment of Resistant Thrombotic Thrombocytopenic Purpura with Rituximab and Cyclophosphamide

OriginalPaper

Clinical Relevance of Survivin as a Biomarker in Neoplasms, Especially in Adult T-Cell Leukemias and Acute Leukemias
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits